Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140


Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.

Roy B, Jackson GR.

Hum Mol Genet. 2014 Jun 1;23(11):3008-23. doi: 10.1093/hmg/ddu011. Epub 2014 Jan 14.


Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.

Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E, Sidhu A.

Eur J Neurosci. 2011 May;33(9):1598-610. doi: 10.1111/j.1460-9568.2011.07660.x. Epub 2011 Apr 1.


Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.

Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A.

PLoS One. 2011 Mar 21;6(3):e17953. doi: 10.1371/journal.pone.0017953.


Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.


Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.

Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A.

Exp Neurol. 2010 Sep;225(1):210-8. doi: 10.1016/j.expneurol.2010.06.017. Epub 2010 Jun 28.


GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Credle JJ, George JL, Wills J, Duka V, Shah K, Lee YC, Rodriguez O, Simkins T, Winter M, Moechars D, Steckler T, Goudreau J, Finkelstein DI, Sidhu A.

Cell Death Differ. 2015 May;22(5):838-51. doi: 10.1038/cdd.2014.179. Epub 2014 Nov 14.


Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.

Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, Sidhu A.

FASEB J. 2006 Nov;20(13):2302-12.


Role of α-synuclein in cognitive dysfunction: Studies in Drosophila melanogaster.

Zhao X, Sun X, Cai S, Ran D, Yan Y, Pei Z.

Mol Med Rep. 2015 Aug;12(2):2683-8. doi: 10.3892/mmr.2015.3763. Epub 2015 May 8.


alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8. Epub 2002 Jul 16.


Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.

Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG.

Neurosci Lett. 2008 Apr 11;435(1):24-9. doi: 10.1016/j.neulet.2008.02.014. Epub 2008 Feb 12.


α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.

Harischandra DS, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG.

Toxicol Sci. 2015 Feb;143(2):454-68. doi: 10.1093/toxsci/kfu247. Epub 2014 Nov 21.


Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.

Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM.

Exp Neurol. 2004 Jun;187(2):279-88.


Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.


Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease.

Harrington AJ, Yacoubian TA, Slone SR, Caldwell KA, Caldwell GA.

J Neurosci. 2012 Feb 8;32(6):2142-53. doi: 10.1523/JNEUROSCI.2606-11.2012.


Early Parkinson's disease symptoms in α-synuclein transgenic monkeys.

Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, Kang Y, Si W, Wang H, Yang SH, Li S, Ji W, Li XJ.

Hum Mol Genet. 2015 Apr 15;24(8):2308-17. doi: 10.1093/hmg/ddu748. Epub 2014 Dec 30.


Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Duka T, Duka V, Joyce JN, Sidhu A.

FASEB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub 2009 Apr 15.


Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.

Taymans JM, Cookson MR.

Bioessays. 2010 Mar;32(3):227-35. doi: 10.1002/bies.200900163.

Items per page

Supplemental Content

Write to the Help Desk